Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Douglas A. McIntyre | Mar 25, 2007 at 4:13 PM EDT

Additional Dendreon Data Ahead of its Provenge FDA Review

I have received comments on Dendreon (DNDN-NASDAQ) for this week that are both positive and negative on how well its…

Douglas A. McIntyre | Mar 23, 2007 at 9:10 AM EDT

Dendreon Interest Remains; Volume Already Beat Average Day

Dendreon (DNDN-NASDAQ) is still getting plenty of trader attention this morning. It is going to post significantly higher volume than…

Douglas A. McIntyre | Mar 23, 2007 at 5:59 AM EDT

Can Amgen Get the Gorilla Off Its Neck?

Shares of biotech giant Amgen (AMGN) fell another 4% last night after the company announced more negative news. The company…

Douglas A. McIntyre | Mar 23, 2007 at 4:04 AM EDT

Thursday’s Top Biotech & Medical Stocks

From BioHealth Investor by H.S. AyoubBioHealth Investor.com Biotechnology OSIRIS THERAPEUTICS [OSIR] +15.40% REXAHN PHARMACEUTICL [RXHN.OB] +12.90% ADVENTRX PHARMACTL [ANX] +10.05%…

Douglas A. McIntyre | Mar 22, 2007 at 3:21 PM EDT

Dendreon’s Stock Activity

Dendreon (DNDN-NASDAQ) started making a mystery move at the end of the day, but you have to look at its…

Douglas A. McIntyre | Mar 22, 2007 at 3:07 AM EDT

Wednesday’s Top Biotech & Medical Stocks

by H.S. AyoubBioHealth Investor.com Biotechnology OSIRIS THERAPEUTICS [OSIR] +12.53% EMERGENT BIOSOLUTION [EBS] +9.25% ZIOPHARM ONCOLOGY IN [ZIOP] +8.91% NANOGEN INC…

Douglas A. McIntyre | Mar 21, 2007 at 5:28 PM EDT

Cramer’s Play on Diabetes

On tonight’s MAD MONEY on CNBC, Jim Cramer said the action of the Defensive Stocks makes you need to watch…

Douglas A. McIntyre | Mar 21, 2007 at 1:47 PM EDT

Conflicts of Interest Statement for FDA Advisory Committees

Did you ever think the FDA or other industry-government regulatory and advisory boards were free from a conflict of interest? …

Douglas A. McIntyre | Mar 21, 2007 at 3:02 AM EDT

Tuesday’s Top Biotech & Medical Stocks

by H.S. AyoubBioHealth Investor.com Biotechnology GENVEC INC [GNVC] +11.51% REXAHN PHARMACEUTICL [RXHN.OB] +10.71% 3SBIO INC [SSRX] +9.64% TERCICA INC [TRCA]…

Douglas A. McIntyre | Mar 20, 2007 at 8:20 AM EDT

As Alzheimer’s Dementia Increases So Could Nursing Home Stocks

The number of people with Alzheimer’s disease rises above five million, one of the questions that come up is who…

Douglas A. McIntyre | Mar 20, 2007 at 4:21 AM EDT

Coated Stent Sales Stay In Reverse

Coated stents cost more than un-coated ones. Putting the drugs onto the coated stents must add expense. But, that means…

Douglas A. McIntyre | Mar 20, 2007 at 3:00 AM EDT

Monday’s Top Biotech & Medical Stocks

Biotechnology ACADIA PHARMACEUTICA [ACAD] +103.44% NEURALSTEM INC [NRLS.OB] +10.51% CYTRX CP [CYTR] +10.19% ACORDA THERAPEUTICS [ACOR] +8.55% REXAHN PHARMACEUTICL [RXHN.OB]…

Douglas A. McIntyre | Mar 19, 2007 at 1:35 PM EDT

Triad (TRI): How Much Higher of a Bid Is There?

Is this the LAST buyout offer for Triad (TRI)? Based on all of the old data, this is now toward…

Douglas A. McIntyre | Mar 19, 2007 at 7:52 AM EDT

Biotech Implosion: AtheroGenics (AGIX)

AtheroGenics Inc. (AGIX-NASDAQ) is the latest biotech implosion this morning. It went from bad to worse as its late-stage clinical…

Douglas A. McIntyre | Mar 19, 2007 at 6:35 AM EDT

Cramer’s Biotech Zombie Looking Up

On Friday’s MAD MONEY on CNBC, Jim Cramer discussed Nastech Pharma (NSTK). This is one of the biotech zombies that…

1 … 376 377 378 379 380 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Additional Dendreon Data Ahead of its Provenge FDA Review

Dendreon Interest Remains; Volume Already Beat Average Day

Can Amgen Get the Gorilla Off Its Neck?

Thursday’s Top Biotech & Medical Stocks

Dendreon’s Stock Activity

Wednesday’s Top Biotech & Medical Stocks

Cramer’s Play on Diabetes

Conflicts of Interest Statement for FDA Advisory Committees

Tuesday’s Top Biotech & Medical Stocks

As Alzheimer’s Dementia Increases So Could Nursing Home Stocks

Coated Stent Sales Stay In Reverse

Monday’s Top Biotech & Medical Stocks

Triad (TRI): How Much Higher of a Bid Is There?

Biotech Implosion: AtheroGenics (AGIX)

Cramer’s Biotech Zombie Looking Up

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Health and Healthcare Articles

All Health and Healthcare Articles

Additional Dendreon Data Ahead of its Provenge FDA Review

Dendreon Interest Remains; Volume Already Beat Average Day

Can Amgen Get the Gorilla Off Its Neck?

Thursday’s Top Biotech & Medical Stocks

Dendreon’s Stock Activity

Wednesday’s Top Biotech & Medical Stocks

Cramer’s Play on Diabetes

Conflicts of Interest Statement for FDA Advisory Committees

Tuesday’s Top Biotech & Medical Stocks

As Alzheimer’s Dementia Increases So Could Nursing Home Stocks

Coated Stent Sales Stay In Reverse

Monday’s Top Biotech & Medical Stocks

Triad (TRI): How Much Higher of a Bid Is There?

Biotech Implosion: AtheroGenics (AGIX)

Cramer’s Biotech Zombie Looking Up

Math Doesn’t Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Featured Reads

Math Doesn't Have Feelings: Dave Ramsey to a Debt-Free Caller Who Feels Like He Has Only $300 Left a Week on $105,000

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62